Analyst Ratings For Akers Biosciences (LON:AKR)
Today, FinnCap reiterated its Corporate rating on Akers Biosciences (LON:AKR).
There are no ratings tracked in the last 12 months. on the stock.
The current consensus rating on Akers Biosciences (LON:AKR) is N/A (Score: NaN) with a consensus target price of GBX 150 per share, a potential .
Some recent analyst ratings include
- 2/24/2017-FinnCap Reiterated Rating of Corporate.
About Akers Biosciences (LON:AKR)
Akers Biosciences, Inc. develops, manufactures and supplies point-of-care screening and testing products designed to bring health-related information to the patient or clinician. The Company’s product offerings and pipeline products focus on delivering diagnostic assistance in a range of healthcare fields/specialties, including cardiology/emergency medicine, metabolism/nutrition, diabetes, respiratory diseases and infectious diseases detection, as well as for on and off-the-job alcohol safety initiatives. The Company’s primary focus is the development and sale of disposable diagnostic testing devices that can be performed in minutes, to facilitate time sensitive therapeutic decisions. The Company’s main products include a disposable breathalyzer test that measures the blood alcohol content of the user, a rapid test detecting the antibody causing an allergic reaction to Heparin and a disposable breathalyzer test that measures Free Radical activity in the human body.
Recent Trading Activity for Akers Biosciences (LON:AKR)
Shares of Akers Biosciences closed the previous trading session at 93.00 down -12.00 -11.43% with 0 shares trading hands.
